02 July 2018 | News
Liquidia boasts an esteemed list of quality lead and co-investors, including visionary venture capital firms, sophisticated family offices, and corporate investment vehicles.
Singapore –Capital raising platform CapBridge Pte Ltd ("CapBridge") is pleased to share that Liquidia Technologies ("Liquidia"), a biopharmaceutical firm that raised millions in funding in its pre-IPO round via CapBridge in 2017, has filed for an IPO on Nasdaq Capital Market. According to Liquidia's filing with the US Securities and Exchange Commission on 28 June 2018, the company plans to raise about $57.5 million in the IPO and list its common stock on the Nasdaq exchange under the ticker LQDA.
Liquidia boasts an esteemed list of quality lead and co-investors, including visionary venture capital firms, sophisticated family offices, and corporate investment vehicles. British pharmaceutical giant GlaxoSmithKline is a key partner of Liquidia, with a broad and multi-year collaboration arrangement.
Investors on the CapBridge Platform who participated in Liquidia's pre-IPO campaign will be rewarded by this milestone liquidity event, in a reasonable period of time.
Quality opportunities led by quality lead investors, such as the Liquidia opportunity demonstrate the key value to investors on the CapBridge platform. The CapBridge process is designed to maximise profitable exit outcomes for all deals on the platform, so that investors can enjoy higher and well risk-adjusted returns.